Economics of Blood Transfusion (TraQ clearinghouse)

Economics of Blood Transfusion

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Created 30 August 2005 | Last updated: 25 Mar. 2009

TraQ clearinghouse for the latest (mainly 2005 and later) literature and news about the costs of blood transfusion

Other literature clearinghouses:
Adverse events | Pretransfusion | Quality systems | Technology to enhance transfusion safety | TM in developing countries

. . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Key: Full text

Also see Economic analyses (UK NBS - systematic review initiative)

Adverse events

Cleemput I, Leys M, Ramaekers D, Bonneux L. Balancing evidence and public opinion in health technology assessments: the case of leukoreduction. Int J Technol Assess Health Care. 2006 Fall;22(4):403–7.

Custer B, Busch MP, Marfin AA, Petersen LR. The cost-effectiveness of screening the U.S. blood supply for West Nile Virus. Ann Int Med 2005 Oct 4;143(7): 486–92.

Summary for patients

Killie MK, Kjeldsen-Kragh J, Husebekk A, Skogen B, Olsen JA, Kristiansen IS. Cost-effectiveness of antenatal screening for neonatal alloimmune thrombocytopenia. BJOG 2007 May;114(5):588–95.

Korves CT, Goldie SJ, Murray MB (2006) Cost-effectiveness of alternative blood screening strategies for West Nile virus in the United States. PLoS Med 2006;3(2): e21

Lee BY, Biggerstaff BJ. Screening the United States blood supply for West Nile Virus: a question of blood, dollars, and sense. (comment) PLoS Med 2006 Feb;3(2):e99

Ezidiegwu CN, Lauenstein KJ, Rosales LG, Kelly KC. Febrile nonhemolytic transfusion reactions. Management by premedication and cost implications in adult patients. Arch Pathol Lab Med 2004 Sep;128(9):991–5.

Postma MJ, van Hulst M, De Wolf JT, Botteman M, Staginnus U. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med. 2005 Oct;15(5):379–87.

Autologous

Goodnough LT. Autologous blood donation (review). Anesthesiol Clin North America 2005 Jun;23(2):263–70.

Dixon S, James V, Hind D, Currie CJ. Economic analysis of the implementation of autologous transfusion technologies throughout England. Int J Technol Assess Health Care 2005 Spring;21(2):234–9.

Mijovic A, Britten C, Regan F, Harrison J. Preoperative autologous blood donation for bone marrow harvests: are we wasting donors' time and blood? Transfus Med 2006 Feb;16(1):57–62.

Rock G, R. Berger R, Bormanis J, Giulivi A, ElSaadany S, Afzal M, J. Beard J, Neurath D, Jones TG. A review of nearly two decades in an autologous blood programme: the rise and fall of activity. Transfus Med 2006 Oct;16(5):307–11.

Blood centres

Hanson TE, Johnson WO, Gastwirth JL. Bayesian inference for prevalence and diagnostic test accuracy based on dual-pooled screening. Biostatistics 2006 Jan;7(1):41–57.

Pitocco C, Sexton TR. Alleviating blood shortages in a resource-constrained environment. Transfusion 2005 Jul; 45(7):1118–26.

Veihola M, Aroviita P, Linna M, Sintonen H, Kekomaki R. International comparison of the technical efficiency of component preparation. Transfusion 2006 Dec;46(12):2109–14.

Competition

Sime SL. Strengthening the service continuum between transfusion providers and suppliers: enhancing the blood services network. Transfusion 2005 Oct;45 Suppl 4:206S–23S.

Decentralizing costs to hospitals

Pinkerton P. The safety, availability and cost-effectiveness of blood transfusion - the impact of decentralizing costs to hospitals. (Ontario Medical Review)

Developing Countries

Rajab JA, Waithaka PM, Orinda DA, Scott CS. Analysis of cost and effectiveness of pre-transfusion screening of donor blood and anti-malarial prophylaxis for recipients. East Afr Med J 2005 Nov;82(11):565–71.

Fractionated and recombinant products

Bolton-Maggs PH. Optimal haemophilia care versus the reality. Br J Haematol 2006 Mar;132(6):671–82.

Bult JM. Perspectives on compensated plasma donation. Dev Biol (Basel). 2005;120:113–7.

Farrugia A. International movement of plasma and plasma contracting. Dev Biol (Basel). 2005; 120:85–96.

Kretschmer V, Weippert-Kretschmer M, Slonka J, Karger R, Zeiler T. Perspectives of paid whole and plasma donation. Dev Biol (Basel). 2005;120:101–11.

Rock G, Akerblom O, Berseus O, Herve P, Jacobs P, Kelly T, et al. The supply of blood products in 10 different systems or countries. Transfus Sci 2000 Jun;22(3):171–82.

Shermock KM, Horn E, Lipsett PA, Pronovost PJ, Dorman T. Number needed to treat and cost of recombinant human erythropoietin to avoid one transfusion-related adverse event in critically ill patients. Crit Care Med 2005 Mar;33(3):497–503.

Solheim BG, Chetty R, Flesland O. Indications for use and cost-effectiveness of pathogen-reduced ABO-universal plasma. Curr Opin Hematol. 2008 Nov;15(6):612–7.

Steinbrook R. Medicare and erythropoietin. N Engl J Med Jan 4;356(1).

General

Ademokun A, Kaznica S, Deas S. Home blood transfusion: a necessary service development. Transfus Med 2005 Jun;15(3):219–22.

Agrawal S, Davidson N, Walker M, Gibson S, Lim C, Morgan CL, Cowell W. Assessing the total costs of blood delivery to hospital oncology and haematology patients. Curr Med Res Opin 2006 Oct;22(10):1903–9.

Beguin C, Closon MC, Vandekerckhove P, Baele P. Concentration of transfusion resources on a few pathologies and a few patients: analysis of the comprehensive in-hospital patient database. Transfusion 2007 Feb;47(2):217–27.

Berger K, Frey L, Spannagl M, Schramm W. [Health economic aspects of the use of blood and blood products.] Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006 Jan;49(1):64–72.

Blumberg N. The costs and consequences of management fads and politically driven regulatory oversight. Arch Pathol Lab Med 1999 Jul;123(7):580-4.

Corwin HL, Hebert P. Avoiding a blood transfusion: How much is it worth? Crit Care Med 2005 Mar; 33(3):672–4.

Custer B, Hoch JS. Cost-effectiveness analysis: what it really means for transfusion medicine decision making. Transfus Med Rev 2009 Jan;23(1):1–12.

Blood Systems Research Institute

Hergon E, Moutel G, Duchange N, Bellier L, Rouger P, Herve C. Risk management in transfusion after the HIV blood contamination crisis in France: the impact of the precautionary principle. Transfus Med Rev 2005 Oct;19(4):273–80.

Kanavos P, Yfantopoulos J, Vandoros C, Politis C. The economics of blood: gift of life or a commodity? Int J Technol Assess Health Care 2006 Summer;22(3):338–43.

Paper on the costs of blood collection, testing, storage, and transfusion in Greece

(No authors listed). The cost of blood: multidisciplinary consensus conference for a standard methodology. Transfus Med Rev 2005 Jan;19(1):66–78.

O'Keeffe T, Refaai M, Tchorz K, Forestner JE, Sarode R. A massive transfusion protocol to decrease blood component use and costs. Arch Surg. 2008 Jul;143(7):686–90; discussion 690–1.

Perez ER, Winters JL, Gajic O. The addition of decision support into computerized physician order entry reduces red blood cell transfusion resource utilization in the intensive care unit. Am J Hematol 2007 Jul;82(7):631–3.

Shander A, Hofmann A, Gombotz H, Theusinger OM, Spahn DR. Estimating the cost of blood: past, present, and future directions. Best Pract Res Clin Anaesthesiol 2007 Jun;21(2):271–89.

Varney SJ, Guest JF. The annual cost of blood transfusions in the UK. Transfus Med 2003 Aug;13(4):205–18.

Wilson K, Hebert PC. The challenge of an increasingly expensive blood system. CMAJ 2003 Apr 29;168(9):1149–50.

Hemapheresis

Borberg H. Quo vadis haemapheresis. Current developments in haemapheresis. Transfus Apher Sci 2006 Feb;34(1):51–73. Full free text

Platelets

Moeremans K, Warie H, Annemans L. Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfus Med 2006 Feb;16(1):17–30.

Red blood cells

Amin M, Fergusson D, Wilson K, Tinmouth A, Aziz A, Coyle D, Hebert P. The societal unit cost of allogenic red blood cells and red blood cell transfusion in Canada. Transfusion 2004 Oct;44(10):1479–86.

Glenngard AH, Persson U, Soderman C. Costs associated with blood transfusions in Sweden - the societal cost of autologous, allogeneic and perioperative RBC transfusion. Transfus Med 2005 Aug;15(4):295–306.

Neri RA, Mason CE, Demko LA. Application of Six Sigma/CAP methodology: controlling blood-product utilization and costs. J Healthc Manag 2008 May–Jun;53(3):183–95; discussion 195–6.

Nissenson AR, Wade S, Goodnough T, Knight K, Dubois RW. Economic burden of anemia in an insured population. J Manag Care Pharm 2005 Sep;11(7):565–74.

Palmieri TL, Lee T, O'Mara MS, Greenhalgh DG. Effects of a restrictive blood transfusion policy on outcomes in children with burn injury. J Burn Care Res. 2007 Jan-Feb;28(1):65–70.

Lechuga D, Thompson C. Cost comparison of methods for preparation of neonatal red cell aliquots. Clin Lab Sci 2007 Winter;20(1):29–31.

Shander A, Hofmann A, Ozawa S, Javidroozi M. The true cost of red blood cell transfusion in surgical patients. ASH Poster Board III 127 (8 Dec. 2008)

Authors use activity based costing principles to determine the cost of a RBC unit in a U.S. hospital ($1158, 2007 value), of which transfusion process cost was 34%. As background, see Essentials of Cost Accounting for Health Care Organizations (2007)

Testing

Szczepura A , Bonsel G, Krauth C, Osipenko L, Haverkamp A. Is fetal RHD typing in all RhD negative women cost effective? (letter) BMJ 2008;336:906 (26 Apr. 2008).

Finning K, Martin P, Summers J, Massey E, Poole G, Daniels G. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. Br Med J (3 April 2008)

	PHSA improves the health of British Columbians by seeking province-wide solutions to specialized health care needs in collaboration with BC health authorities and other partners. For more information, visit www.phsa.ca

PHSA agencies include: BC Cancer Agency, BC Centre for Disease Control, BC Children’s Hospital and Sunny Hill Health Centre for Children, BC Mental Health & Addiction Services, BC Provincial Renal Agency, BC Transplant, BC Women’s Hospital & Health Centre, and Cardiac Services BC.